02Jan 2019

NEXT-GENERATION SEQUENCING (NGS): OUR RESULTS OF MOLECULAR PATHOLOGY MALIGNANT SOLID TUMOR PANEL.

  • Aydin Adnan Menderes University, Medical Faculty, Department of Pathology.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Next-generation sequencing (NGS) has been widely used in cancer development, diagnosis and treatment in recent years. It offers new possibilities for the detection of mutations in malignant solid tumors.In this study, the results of malignant solid tumors with NGS were evaluated. A total of 263 NGS cancer cases were included in the study.A total of 345 mutations were detected by the NGS 12 gene panel. The most common mutation was observed in NSCLC cases. The most common K-ras mutation was observed in all cancers. More than one mutation was detected in 71.8 % of the cases. The mutations showing the most frequent accumulation are K-ras, PIK3CA mutations. NGS, which is a fast and easy method, provides new possibilities in diagnosis, treatment and carcinogenesis in cancer cases. According to the study results, there were more than one mutation in malignant solid tumors. The selection of NGS panel should be based on the type of cancer and regional differences. In order to determine the effect of additional mutations on the treatment and prognosis in cancers with more than one mutation, studies should be conducted with a large series of cases.

  1. Al-Kateb H, Nguyen TT, Steger-May K, Pfeifer JD (2015). Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). MolOncol 9:1737?1743.
  2. Cancer Genome Atlas Research Network (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543?550.
  3. Damodaran S, Berger MF, Roychowdhury S (2015) Clinical tumor sequencing: Opportunities and challenges for precision cancer medicine. Am SocClinOncolEducBook e175?e182.
  4. Del Vecchio F, Mastroiaco V, Di Marco A, Compagnoni C, Capece D, Zazzeroni F, Capalbo C, Alesse E, Tessitore A,(2017).Next-generation sequencing: recent applications to the analysis of colorectal cancer. J Transl Med 15:246:1-19.
  5. D?Haene N, Fontanges Q, De N?ve N, Blanchard O, Melendez B, Delos M, Dehou MF, Maris C, et al. (2018).Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. Oncotarget 9; 29: 20761-20768.
  6. Goodwin S, McPherson, JD, McCombie, WR, (2016). Coming of age: Ten years of next-generation sequencing technologies. Nat Rev Genet 17, 333?351.
  7. Kamps R, Brand?o RD, van den Bosch BJ, Paulussen ADC, Xanthoulea S, Blok MJ, Romano A (2017). Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int J MolSci 18, 308;1-57.
  8. Koitzsch U, Heydt C, Attig H, Immerschitt I, Merkelbach-Bruse S, Fammartino A, B?ttner RH, Kong Y, Odenthal M (2017). Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study. J ClinPathol 70:725?728.
  9. Lawrence MS Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL,
  10. Stewart C, Mermel CH, Roberts SA, et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214?218.
  11. Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R (2015). On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients. Mol Cancer Ther 14: 1488?1494.
  12. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, et al. (2014) Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genesfor mutations and copy number variations in solid tumours. Br J Cancer 111: 2014?2023.
  13. Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, Vaccari EM, Bissonnette J, Booke JK, Cremona ML, et al. (2016). Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med 18, 823?832.
  14. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, Wells WA, Amos CI (2014) Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. ClinChem Lab Med 52: 707?714.
  15. Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, et al. (2016). Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med 8: 62.
  16. Yu B, O?Toole SA, Trent RJ (2015). Somatic DNA mutation analysis in targeted therapy of solid tumours. TranslPediatr 2015 4: 125?138.

[Ibrahim Halil Erdogdu. (2019); NEXT-GENERATION SEQUENCING (NGS): OUR RESULTS OF MOLECULAR PATHOLOGY MALIGNANT SOLID TUMOR PANEL. Int. J. of Adv. Res. 7 (Jan). 306-311] (ISSN 2320-5407). www.journalijar.com

IBRAHIM HALIL ERDOGDU
AYDIN ADNAN MENDERES UNIVERSITY, MEDICAL FACULTY, DEPARTMENT OF PATHOLOGY

DOI:

Article DOI: 10.21474/IJAR01/8328      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8328

Download Full Paper

Download PDF No. of Downloads: 14 | No. of Views: 76